Midatech Pharma (Midatech) has announced the extension of its Q-Sphera R&D collaboration deal with Janssen, its European partner since July 2020. The extension includes further optimisation (bio delivery) of Janssen’s experimental monoclonal antibody (mAb), which Midatech had successfully encapsulated using its Q-Sphera technology, as announced in June 2021. The company has an existing three-asset collaboration agreement with Janssen (to develop long-acting injectable versions of its undisclosed active pharmaceutical ingredients) and delivered proof-of-concept on two of the programmes in H221 (MTX214 and MTX216).